Mirjam B Zeisel - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Mirjam B Zeisel

Showing results (101-110 of 103) with videos related to

Pageof 11

Sort By:

You have reached the last page of results.This site can display upto 103 results.

Journal of Hepatology|October 29, 2022

Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironmentNatascha Roehlen, Marion Muller, Zeina Nehme, et al.

Science Translational Medicine|December 21, 2022

A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticityNatascha Roehlen, Antonio Saviano, Houssein El Saghire, et al.

Nature Communications|September 18, 2021

A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discoveryEmilie Crouchet, Simonetta Bandiera, Naoto Fujiwara, et al.

Pageof 11

Search research articles

Showing results (101-110 of 103) with videos related to

Sort By:

Pageof 11

You have reached the last page of results.This site can display upto 103 results.

Journal of Hepatology|October 29, 2022

Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironmentNatascha Roehlen, Marion Muller, Zeina Nehme, et al.

Science Translational Medicine|December 21, 2022

A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticityNatascha Roehlen, Antonio Saviano, Houssein El Saghire, et al.

Nature Communications|September 18, 2021

A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discoveryEmilie Crouchet, Simonetta Bandiera, Naoto Fujiwara, et al.

Pageof 11